Prevention of cardiovascular disease: Much more is needed

GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1260–1344.

Tunstall-Pedoe H (ed.) for the MONICA Project. MONICA Monograph and multimedia sourcebook. Geneva: World Health Organization, 2003.

O’Flaherty M Huffman MD Capewell S . Declining trends in acute myocardial infarction attack and mortality rates, celebrating progress and ensuring future success. Heart 2015; 101: 1353–1354.

Kotseva K Wood D De Bacquer D et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–648.

Kotseva K De Bacquer D De Backer G et al. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol 2016; 23: 2007–2018.

Banegas JR Lopez-Garcia E Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: The EURIKA study. Eur Heart J 2011; 32: 2143–2152.

Hermans MP Castro Cabezas M Strandberg T et al. Centralized pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): Overall findings from eight countries. Curr Med Res Opin 2010; 26: 445–454.

Gitt AK Drexel H Feely J et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012; 19: 221–230.

Webster RJ Heeley EL Peiris DP et al. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust 2009; 191: 324–329.

Yusuf S Rangarajan S Teo K et al. for the PURE Investigators. Cardiovascular risk and events in 17 low-, middle- and high-income countries. N Engl J Med 2014; 371: 818–827.

Arafah M Al-Hinai AT Al Mahmeed W et al. Centralized pan-Middle East survey on the undertreatment of hypercholesterolemia: Results from the CEPHEUS study in Arabian Gulf countries. Angiology 2014; 65: 919–926.

Park JE Chiang CE Munawar M et al. Lipid-lowering treatment in hypercholesterolaemic patients: The CEPHEUS pan-Asian survey. Eur J Prev Cardiol 2012; 19: 781–794.

Al Sifri SN Almahmeed W Azar S et al. Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One 2014; 9: e84350–e84350.

Bhatt DL Steg PG Ohman EM et al. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–189.

Mendis S Abegunde D Yusuf S et al. WHO study on Prevention and Recurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005; 83: 820–828.

Danchin N Almahmeed W Al-Rasadi K et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018 25: 1087–1094.

Reiner Z Catapano AL De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818.

Conroy RM Pyörälä K Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24: 987–1003.

World Health Organization. Prevention of cardiovascular disease: Guidelines for assessment and management of cardiovascular risk, Geneva: World Health Organization, 2007.

US Department of Health and Human Services, NIH, NHLBI. Your guide to lowering your cholesterol with TLC. NIH publication no. 06-5235. US Department of Health and Human Services, 2005.

Karlson BW Wiklund O Palmer MK et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin and simvastatin: Results from VOYAGER. Eur Heart J Cardiovasc Pharmacother 2016; 2: 212–217.

Cannon CP Blazing MA Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387–2397.

Sabatine MS Giugliano RP Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Steg G, Schwartz GG, Szarek M, et al. The Odyssey outcomes trial: Topline results. Alirocumab in patients after acute coronary syndrome. ACC 67th scientific sessions, Orlando, Florida, USA, 10 March 2018.

Fuster V Gambus F Patriciello A et al. The polypill approach – an innovative strategy to improve cardiovascular health in Europe. BMC Pharmacol Toxicol 2017; 18: 10–10.

World Health Organization. Global action plan for the prevention and control of non-communicable diseases, Geneva: World Health Organization, 2013.

Corra U Piepoli MF . Secondary prevention: Where we are. In: Guazzi M, Lambrinou E and Vrints C (eds) Essentials of secondary prevention. Eur J Prev Cardiol 2017; 24(3S): 14–21.